You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

MEGESTROL ACETATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for megestrol acetate and what is the scope of freedom to operate?

Megestrol acetate is the generic ingredient in three branded drugs marketed by Bristol Myers Squibb, Endo Operations, Chartwell, Hikma, Novitium Pharma, Strides Pharma, Teva Pharms, Twi Pharms, Xttrium Labs Inc, Barr, Teva, and Usl Pharma, and is included in eighteen NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Megestrol acetate has thirty-six patent family members in nineteen countries.

There are seventeen drug master file entries for megestrol acetate. Sixteen suppliers are listed for this compound.

Drug Prices for MEGESTROL ACETATE

See drug prices for MEGESTROL ACETATE

Recent Clinical Trials for MEGESTROL ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1/Phase 2
Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshPhase 2
Ontario Institute for Cancer ResearchPhase 1

See all MEGESTROL ACETATE clinical trials

Pharmacology for MEGESTROL ACETATE
Drug ClassProgestin
Medical Subject Heading (MeSH) Categories for MEGESTROL ACETATE
Paragraph IV (Patent) Challenges for MEGESTROL ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MEGACE ES Oral Suspension megestrol acetate 125 mg/mL 021778 1 2011-04-27

US Patents and Regulatory Information for MEGESTROL ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Usl Pharma MEGESTROL ACETATE megestrol acetate TABLET;ORAL 070646-001 Oct 2, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Twi Pharms MEGESTROL ACETATE megestrol acetate SUSPENSION;ORAL 203139-001 Aug 27, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Xttrium Labs Inc MEGESTROL ACETATE megestrol acetate SUSPENSION;ORAL 076721-001 Nov 1, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MEGESTROL ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Operations MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 ⤷  Sign Up ⤷  Sign Up
Endo Operations MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb MEGACE megestrol acetate SUSPENSION;ORAL 020264-001 Sep 10, 1993 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.